Dogan Emine, Sever Ozkan, Köklü Çakır Burcin, Celik Erkan
Department of Ophthalmology, Sakarya University Medical Education and Research Hospital, Sakarya, Turkey.
Department of Ophthalmology, Namik Kemal University School of Medicine, Namik Kemal University, Tekirdag, Turkey,
Clin Ophthalmol. 2018 Aug 17;12:1465-1470. doi: 10.2147/OPTH.S162019. eCollection 2018.
The aim of this study was to evaluate the effect of initial intravitreal ranibizumab injection on visual acuity (VA) and central macular thickness (CMT) for the treatment of macular edema (ME) with and without serous retinal detachment (SRD) secondary to branch retinal vein occlusion (BRVO).
Fifty-two BRVO eyes, treated with intravitreal ranibizumab injection for ME with and without SRD, were retrospectively reviewed. Patients were divided into two groups according to spectral domain optical coherence tomography (SD-OCT). The efficacy of intravitreal ranibizumab injection at first month was assessed by analyzing the change in best-corrected VA and reduction in CMT with SD-OCT.
There were 21 patients with SRD and 31 patients with only CME (no-SRD). CMT was significantly greater in the SRD group than in the CME group (451±62.2 µm vs 383.5±37.2 µm, respectively, <0.05). After initial intravitreal ranibizumab injection, mean VA improved from 0.87±0.26 logarithm of the minimum angle of resolution (LogMAR) to 0.54±0.27 LogMAR (<0.01) and CMT decreased from 451±62.2 µm to 379.3±58.6 µm (<0.001) in the SRD group. In the no-SRD group, mean VA improved from 0.69±0.25 LogMAR to 0.44±0.25 LogMAR (<0.001) and the CMT decreased from 383.5±37.2 µm to 337.7±39.4 µm (<0.001) at the first month visit. Eyes with SRD revealed better anatomic results and greater reduction of CMT after intravitreal ranibizumab injection (<0.01).
VA and CMT can be improved by intravitreal ranibizumab injection in BRVO patients with and without SRD. However, more marked improvement in macular morphology was achieved in patients with SRD than those without SRD.
本研究旨在评估玻璃体内注射雷珠单抗初始治疗对伴有或不伴有视网膜分支静脉阻塞（BRVO）继发浆液性视网膜脱离（SRD）的黄斑水肿（ME）患者视力（VA）和中心黄斑厚度（CMT）的影响。
回顾性分析52只接受玻璃体内注射雷珠单抗治疗ME伴或不伴SRD的BRVO患眼。根据频域光学相干断层扫描（SD-OCT）将患者分为两组。通过分析最佳矫正视力的变化以及SD-OCT测量的CMT降低情况，评估玻璃体内注射雷珠单抗第1个月时的疗效。
21例患者伴有SRD，31例患者仅患有黄斑囊样水肿（无SRD）。SRD组的CMT显著高于CME组（分别为451±62.2μm和383.5±37.2μm，P<0.05）。玻璃体内注射雷珠单抗初始治疗后，SRD组平均视力从最小分辨角对数（LogMAR）0.87±0.26提高到0.54±0.27（P<0.01），CMT从451±62.2μm降至379.3±58.6μm（P<0.001）。在无SRD组，第1个月复诊时平均视力从LogMAR 0.69±0.25提高到0.44±0.25（P<0.001），CMT从383.5±37.2μm降至337.7±39.4μm（P<0.001）。伴有SRD的患眼在玻璃体内注射雷珠单抗后显示出更好的解剖学结果和更大程度的CMT降低（P<0.01）。
玻璃体内注射雷珠单抗可改善伴有或不伴有SRD的BRVO患者的VA和CMT。然而，伴有SRD的患者黄斑形态改善比不伴有SRD的患者更显著。
